Clinical Trials Logo
  1. Home
  2. Prostate Cancer Recurrent
  3. NCT04114825

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer — BRaVac  

Prostate Cancer Recurrent Clinical Trial

Official title:
A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)

Clinical Trial Summary

This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04114825
Study type Interventional
Source RhoVac APS
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 19, 2019
Completion date November 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT02562131 - PET-MR-PSA Prostate Cancer Recidive Study
Completed NCT04134130 - The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer N/A
Recruiting NCT03507595 - Evaluation of the Metastasis and Recurrence of Prostate Cancer
Active, not recruiting NCT04983628 - Molecular Profiling in Prostate Cancer
Completed NCT03739684 - Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Phase 3
Recruiting NCT04686188 - Exploring the Mechanisms and Dynamics of Clonal Evolution Leading to Recurrence in Prostate Cancer
Recruiting NCT05646550 - Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer Phase 1
Not yet recruiting NCT04876755 - MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer Phase 2
Recruiting NCT01938339 - Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer N/A
Completed NCT01857037 - Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI N/A
Active, not recruiting NCT03444844 - Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Phase 1/Phase 2
Completed NCT04102553 - F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence Phase 3
Completed NCT03443609 - Study of 68Ga-HBED-PSMA PET/CT and Conventional Imaging in Occult Biological Relapse Prostate Cancer N/A
Recruiting NCT05036226 - COAST Therapy in Advanced Solid Tumors and Prostate Cancer Phase 1/Phase 2
Completed NCT04324983 - Identification of Predictive Biomarkers N/A
Completed NCT02176161 - Metformin Prostate Cancer Adjuvant Trial Phase 2
Active, not recruiting NCT04734184 - A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer Phase 3
Not yet recruiting NCT04312191 - Using Meditation for Oncology Anxiety N/A